Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00861744 · ClinicalTrials.gov registry record · Phase 2

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

A Phase 2 study of Measles and Mumps, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
1,259
Enrollment target
20
Study locations

NCT00861744 is a Phase 2 study of Measles and Mumps that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,259 participants, below the 2,421-participant average among 4 other Measles trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00861744, a Phase 2 study of Measles and Mumps, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
1,259 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. Additionally, antibody persistence will be assessed one and two years after administration of MMR vaccine. The Protocol Posting has been updated following Protocol amendment 1 and 2, Oct 2009.

Conditions Studied

Measles Mumps Rubella Measles-Mumps-Rubella Vaccine

Interventions

  • BIOLOGICAL GSK Biological's investigational vaccine 209762
  • BIOLOGICAL M-M-R® II (Merck and Co)
  • BIOLOGICAL Varivax®
  • BIOLOGICAL Havrix®
  • BIOLOGICAL Prevnar®

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Downey
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - Huntington Beach
  • GSK Investigational Site - Paramount
  • GSK Investigational Site - Santa Ana
  • GSK Investigational Site - West Covina

Arkansas

  • GSK Investigational Site - Conway
  • GSK Investigational Site - Jonesboro
  • GSK Investigational Site - Little Rock

Georgia

  • GSK Investigational Site - Dalton
  • GSK Investigational Site - Marietta

Louisiana

  • GSK Investigational Site - Bossier City
  • GSK Investigational Site - Metairie

Alabama

  • GSK Investigational Site - Tuscaloosa

Florida

  • GSK Investigational Site - Altamonte Springs

Idaho

  • GSK Investigational Site - Nampa

Illinois

  • GSK Investigational Site - DeKalb

Trial Details

FieldValue
Enrollment Target 1,259 participants
Start Date 2009-06-03
Est. Completion 2012-06-18
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00861744

The ClinicalTrials.gov registry entry for NCT00861744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,259 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,421-participant average among 4 other Measles trials with a reported enrollment target (48% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Measles appearing as the primary indexed condition, and to 5 interventions - of which GSK Biological's investigational vaccine 209762 is the first listed.

NCT00861744 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Arkansas, Georgia.

Frequently Asked Questions

What is clinical trial NCT00861744 about?

NCT00861744 is a clinical study titled "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age". The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. Additionally, antibody persistence will be assessed one and t...

What is the current status of trial NCT00861744?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,259 participants. The study started on 2009-06-03. Estimated completion is 2012-06-18.

What conditions does trial NCT00861744 study?

This clinical trial studies the following conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine.

What interventions are being tested in trial NCT00861744?

The interventions under investigation include: GSK Biological's investigational vaccine 209762 (BIOLOGICAL), M-M-R® II (Merck and Co) (BIOLOGICAL), Varivax® (BIOLOGICAL), Havrix® (BIOLOGICAL), Prevnar® (BIOLOGICAL).

Who is sponsoring clinical trial NCT00861744?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00861744 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Measles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Measles

All registered trials for this condition

Mumps

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.